Astria Therapeutics【ATXS】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

7.86

買値

7.71

売値

8.60

出来高

450,786

7.51 日の範囲 7.95

7.16 52 週間の範囲 16.90

時価総額

443.573M

前日終値

7.49

始値

7.7285

時刻

最終取引時間

財務取引量

US$ 3,488,185

VWAP

7.738

平均取引量 (3 か月)

327,188

発行済株式数

56,434,219

配当利回り

PER

-6.61

1 株当たり利益 (EPS)

-1.29

歳入

純利益

-72.89M

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for... Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.astriatx.com

本社

Wilmington, Delaware, USA

設立

Astria Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ATXS. The last closing price for Astria Therapeutics was US$7.49. Over the last year, Astria Therapeutics shares have traded in a share price range of US$ 7.16 to US$ 16.90.

Astria Therapeutics currently has 56,434,219 shares in issue. The market capitalisation of Astria Therapeutics is US$422.69 million. Astria Therapeutics has a price to earnings ratio (PE ratio) of -6.61.

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

-- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing...

Form 8-K - Current report

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650...

Form 8-K - Current report

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

-- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67...

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.34	4.52127659574	7.52	8	7.3	268859	7.47033245	CS
4	-1.15	-12.7635960044	9.01	9.15	7.16	304964	7.69926889	CS
12	-3.92	-33.2767402377	11.78	12.1	7.16	327188	9.19635026	CS
26	-3.69	-31.9480519481	11.55	12.92	7.16	323692	10.4296476	CS
52	-5.12	-39.4453004622	12.98	16.9	7.16	540710	11.72317103	CS
156	3.94	100.510204082	3.92	16.9	2.36	323106	10.43783091	CS
260	-0.67	-7.85463071512	8.53	16.9	2.36	292320	10.36064716	CS

ATXS - Frequently Asked Questions (FAQ)

What is the current Astria Therapeutics share price?

The current share price of Astria Therapeutics is US$ 7.86

How many Astria Therapeutics shares are in issue?

Astria Therapeutics has 56,434,219 shares in issue

What is the market cap of Astria Therapeutics?

The market capitalisation of Astria Therapeutics is USD 422.69M

What is the 1 year trading range for Astria Therapeutics share price?

Astria Therapeutics has traded in the range of US$ 7.16 to US$ 16.90 during the past year

What is the PE ratio of Astria Therapeutics?

The price to earnings ratio of Astria Therapeutics is -6.61

What is the reporting currency for Astria Therapeutics?

Astria Therapeutics reports financial results in USD

What is the latest annual profit for Astria Therapeutics?

The latest annual profit of Astria Therapeutics is USD -72.89M

What is the registered address of Astria Therapeutics?

The registered address for Astria Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Astria Therapeutics website address?

The website address for Astria Therapeutics is www.astriatx.com

Which industry sector does Astria Therapeutics operate in?

Astria Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	US$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	US$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	US$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	US$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	US$ 2.0899 (-46.41%)	1.57M
NIVFNewGenIvf Group Ltd	US$ 0.1489 (-42.51%)	14.8M
GLSTGlobal Star Acquisition Inc	US$ 8.83 (-39.10%)	23.89k
PRPHProPhase Labs Inc	US$ 0.2633 (-38.02%)	872.46k
SPGCSacks Parente Golf Inc	US$ 0.5601 (-37.86%)	7.27M
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
NVDANVIDIA Corporation	US$ 120.07 (-3.67%)	388.54M
RIMEAlgorhythm Holdings Inc	US$ 0.02565 (5.12%)	338.75M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0355 (-11.25%)	236.29M
CLEUChina Liberal Education Holdings Ltd	US$ 0.1938 (30.77%)	234.8M